【摘要】 目的探讨雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)在乳腺癌患者新辅助化疗前后的表达变化及临床意义。方法采用免疫组织化学染色法检测154例乳腺癌患者新辅助化疗前后的ER、PR和HER-2的表达变化。结果新辅助化疗前后的ER、PR和HER-2表达阳性率差异均无统计学意义(P>0.05);ER、PR和HER-2的阳性-阴性表达转化率分别为26.0%、28.0%和31.0%,以PR和HER-2丢失更为常见(P<0.05)。结论 ER、PR和HER-2的表达变化可作为指导乳腺癌新辅助化疗的重要指标。更多还原

【Abstract】 Objective To investigate the changes and clinical significance of the expressions of estrogen receptor(ER),progesterone receptor(PR)and humanized epidermal growth factor receptor 2(HER-2)before and after neoadjuvant chemotherapy(NAC)in the patients with breast cancer.Methods The changes of ER,PR and HER-2expressions were detected by immunohistochemistry in154 patients with breast cancer before and after NAC.Results The positive rates of ER,PR and HER-2expressions before and after NAC were not statistically different(P>0.05).The conversion rates of positive and negative expression were 26.0%,28.0% and 31.0% for ER,PR and HER-2,respectively,in which the loss of PR and HER-2 was more common(P<0.05).Conclusion The changes in ER,PR and HER-2expressions may be the important indicators for pre-and post-NAC treatment in the patients with breast cancer.更多还原